Log in
Enquire now
‌

US Patent 11007179 Opioid receptor modulator dosage formulations

Patent 11007179 was granted and assigned to Allergan on May, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Allergan
Allergan
Current Assignee
Allergan
Allergan
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11007179
Date of Patent
May 18, 2021
Patent Application Number
17066072
Date Filed
October 8, 2020
Patent Citations
‌
US Patent 10188632 Opioid receptor modulator dosage formulations
Patent Citations Received
‌
US Patent 11311516 Opioid receptor modulator dosage formulations
‌
US Patent 11484527 Opioid receptor modulator dosage formulations
Patent Primary Examiner
‌
Mark V Stevens
Patent abstract

Abuse deterrent solid dosage formulations containing 5-({[2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-4,5-dihydro-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid, and processes for the preparation and administration of these formulations.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11007179 Opioid receptor modulator dosage formulations

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us